AlphAIalphai — Financial news for AI agents
Insider MonkeyMAR 53 min read$ARCT

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 Earnings Call Transcript

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) discussed its Q4 2025 earnings, reporting an EPS miss. The call focused on the advancement of its mRNA therapeutic candidates, ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase deficiency, highlighting progress in clinical trials and regulatory interactions. The company also provided updates on its partnered COVID-19 vaccine program and its financial position, including a cash runway extended into Q2 2028.

Original reporting
Insider Monkey
Published Mar 5, 2026, 1:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 5, 2026, 2:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 Earnings Call Transcript — source image
Source · Insider Monkey
Decision brief

The 30-second read

$ARCTNeutralMed
01

Why it matters

Clinical progress and financial stability may support future valuation despite current earnings miss.

02

Market read

The company's clinical and financial updates are relevant for biotech investors, especially those focused on mRNA technology.

03

What to watch

Potential upcoming catalysts include regulatory approvals and partnership developments that could offset short-term earnings concerns.

Timing: Moderate; clinical trial updates and earnings reports are relevant over the next 1-3 months.

Background

Arcturus Therapeutics is advancing its mRNA therapeutic pipeline amid a challenging earnings environment.

Company-level read

Ticker impact

$ARCTNeutralMedium confidence
Context

Primary focus of the news due to Q4 2025 earnings report and clinical progress.

Expected impact

Potential short-term decline followed by stabilization or slight recovery as clinical progress is recognized.

Evidence & confidence

Earnings miss may cause initial negative reaction; however, positive clinical updates and extended cash runway support a cautiously optimistic outlook.

Market effects

Sector

Potential positive influence on biotech sector, especially mRNA therapeutics, as clinical progress continues.

Regional

Limited; primarily affects US biotech stocks.

Global

Moderate; advances in mRNA therapeutics could influence global biotech innovation and investment trends.

Counterpoint

What could challenge this read

The earnings miss may be temporary; if clinical trials continue to show promise, the stock could rebound strongly.

Key entities

  • Company
    Arcturus Therapeutics Holdings Inc.

    Biotech company specializing in mRNA therapeutics.

  • Drug Candidate
    ARCT-032

    mRNA therapy for cystic fibrosis.

  • Drug Candidate
    ARCT-810

    mRNA therapy for ornithine transcarbamylase deficiency.

Read at source← All news

Related articles

AUG 7
$ARCTMed

Arcturus and CSL Seqirus terminate sa-mRNA vaccine partnership

Arcturus Therapeutics (Nasdaq: ARCT) terminated its sa-mRNA vaccine partnership with CSL Seqirus via a settlement. Arcturus regained global rights to KOSTAIVE (ARCT-154) and other vaccine programs. CSL Seqirus will pay $12m cash, and Arcturus is released from about $16m in R&D credits, totaling about $28m. The deal unwinds a pact valued around $4.3b.

allsci.com4 min
AUG 6
$ARCTMed

Arcturus Therapeutics Holdings Inc. (ARCT): Results of Operations and Financial Condition

Arcturus Therapeutics Holdings Inc. (ARCT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 e665679_ex99-1.htm Arcturus Therapeutics Announces Second Quarter 2026 Financial Results and Pipeline Progress ARCT-032 (CF) Phase 2 study enrollment remains on schedule; the decision to proceed into Phase 3 expected Q4 2026 ARCT-810 (OTC Deficiency) Phase 2 study enrol

SEC EDGAR 8-K6 min
JUL 2
$ARCTMed

Arcturus Therapeutics Stock Rises 8% On Thermo Fisher Collaboration

Arcturus Therapeutics (ARCT) shares rose 7.84% to $7.43 on Nasdaq after the company said it entered a strategic collaboration with Thermo Fisher Scientific to support Phase 3 development and potential commercialization of ARCT-032 for cystic fibrosis. Thermo Fisher will provide manufacturing, clinical research and commercialization support via its Accelerator platform, with exclusive commercial manufacturing rights if approved.

rttnews.com2 min
JUL 2
$TMOMed

Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy - Thermo Fisher Scientific (NYSE:TMO), Ar

Arcturus Therapeutics said it selected Thermo Fisher Scientific to support Phase 3 development of ARCT-032, an inhaled mRNA therapy for cystic fibrosis. Thermo Fisher will provide Phase 3 manufacturing and clinical research services, with Phase 3 expected to run via Thermo Fisher’s PPD if Phase 2 is positive. A separate deal could grant exclusive commercial manufacturing rights if ARCT-032 is approved. Arcturus shares were up 12.19% to $7.73.

benzinga.com3 min
JUL 2
$ARCTMed

Arcturus Therapeutics gains 5.8% on Thermo Fisher deal By Investing.com

Arcturus Therapeutics (NASDAQ:ARCT) rose 5.8% premarket after announcing a collaboration with Thermo Fisher Scientific (NYSE:TMO) for late-stage development and commercialization support of ARCT-032, an experimental mRNA cystic fibrosis treatment. Thermo Fisher will provide manufacturing and clinical research services; Arcturus expects to use Thermo Fisher’s clinical research business if mid-stage data are positive and grants exclusive commercial manufacturing rights if approved.

investing.com3 min
AUG 9
$AAPLMed

Apple Tests Chinese Memory Chips As Supply Crunch Pushes PC Giants Toward CXMT

The Wall Street Journal reported Apple is testing memory chips from China’s CXMT across iPhones and MacBooks and has held early talks to supply components for some China-sold devices. Apple is seeking White House approval amid “unsustainable” pricing from SK Hynix, Samsung, Micron and SanDisk. US rules limit customization, but off-the-shelf purchases may be allowed.

zerohedge.com6 min